Interim Injunction on Zydus’s biosimilar Sigrima: Roche’s Commercial Motivation?

The interim injunction issued by the Delhi High Court on July 9, 2024, stems from significant concerns raised by Roche’s senior counsel. The Court found compelling reasons to issue an injunction, restraining Zydus from marketing/selling Sigrima until the next hearing date. Interacting with ETPharma an expert in the know-how of the ongoing legal battle based on anonymity highlighted that in terms of affordability and accessibility, the annual cost of Perjeta is Rs 47.6 lakh, which will be reduced to Rs 13.5 lakh with Sigrima—almost one-fourth of the cost.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/0m8vwu6
via